Serum not contracted for complete production of COVID vaccine to centre
These media reports are based on incorrect facts and are without any basis.
These media reports are based on incorrect facts and are without any basis.
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated